Conbercept Efficacious In Short-Term Treatment Of Diabetic Macular Edema With Or Without Diabetic Nephropathy
- byDoctor News Daily Team
- 02 August, 2025
- 0 Comments
- 0 Mins
Diabetic macular edema (DME) is a common complication of diabetes, and when coupled with diabetic nephropathy (DN), it poses additional challenges to management. In a recent retrospective study, researchers aimed to evaluate the therapeutic effects of conbercept on DME patients with and without DN.
This study was published in the International Journal Of Ophthalmology by Zhu YZ and colleagues.
The study included 54 patients diagnosed with DME, categorized into two groups: those with DN (25 eyes) and those without DN (29 eyes). Various parameters, including fasting blood glucose, HbA1c, microalbumin/creatinine, serum creatinine, central macular thickness (CMT), best corrected visual acuity (BCVA), and retinal hyperreflective foci (HF), were assessed before and during treatment. Optical coherence tomography (OCT) was utilized to evaluate ellipsoidal zone (EZ) and external limiting membrane (ELM) integrity.
The key findings of the study were:
Significant differences were observed between the two groups in fasting blood glucose, HbA1c, serum creatinine, urinary microalbumin/creatinine, and estimated glomerular filtration rate (eGFR).
EZ and ELM continuity were worse in the DME+DN group.
BCVA was significantly better in the DME group compared to the DME+DN group throughout treatment. CMT and HF values were higher in the DME+DN group and decreased with treatment in both groups over time.
The mean number of injections at 6 months was higher in the DME+DN group compared to the DME group.
Conbercept demonstrated significant efficacy in the short-term treatment of DME, with or without DN. It improved BCVA, CMT, and reduced HF counts. However, treatment efficacy was better in DME patients without DN. These findings highlight the potential of conbercept in managing DME, particularly in patients without DN. Further research is warranted to validate these results and explore long-term outcomes.
Reference:
Zhu YZ, Dou ZZ, Wang WY, Ma QY, Yi WD, Yao NN, Liu YC, Gao XD, Zhang Q, Luo WJ. Intravitreal injection of conbercept for diabetic macular edema complicated with diabetic nephropathy
DOI:10.18240/ijo.2024.02.12
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
Recent News
Pfizer files lawsuit against Metsera, its Director...
- 02 November, 2025
Health Ministry achieves 3 Guinness World Records...
- 02 November, 2025
Roche gets CE mark for Elecsys Dengue Ag test to d...
- 02 November, 2025
Daily Newsletter
Get all the top stories from Blogs to keep track.
0 Comments
Post a comment
No comments yet. Be the first to comment!